# Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)

> **NCT06045793** · PHASE2 · TERMINATED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 3 (actual)

## Conditions studied

- Cocaine Use
- Cocaine Intoxication
- Cocaine Toxicity
- Cocaine Abuse
- Cocaine Adverse Reaction

## Interventions

- **DRUG:** TNX-1300 (Injection)
- **DRUG:** Placebo (Injection)

## Key facts

- **NCT ID:** NCT06045793
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-08-16
- **Primary completion:** 2025-04-21
- **Final completion:** 2025-04-21
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Tonix has discontinued enrollment and terminated the Phase 2 CATALYST study (TNX-CE-CI202) because enrollment in this emergency department-based study was slower than projected. The study was not discontinued for safety or efficacy reasons.
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06045793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06045793, "Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06045793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*